कंपनी का अवलोकन
Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of therapeutic interventions for prevalent retinal diseases. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high level of scientific risk and reliance on successful clinical trial outcomes for future commercial viability. The current market capitalization stands at $139.17M, while the annual revenue and employee count are recorded as N/A and 20 respectively. The market capitalization of $139.17M indicates a small-cap enterprise typical of early-stage biotechnology firms that have not yet achieved significant commercial revenue streams or large-scale operational infrastructure. With only 20 employees, the company maintains a lean operational structure characteristic of clinical-stage development, where resources are heavily concentrated on research and development activities rather than extensive sales or manufacturing operations. The absence of reported annual revenue in the available data underscores the pre-commercial nature of the business, where value is derived from intellectual property and pipeline potential rather than current sales performance.
वित्तीय स्वास्थ्य
The reported net income for the trailing twelve months is $-43,438,000, while revenue and EBITDA figures are listed as N/A and $-46,139,000 respectively. The significant disparity between the net income of $-43,438,000 and the EBITDA of $-46,139,000 reveals a cost structure dominated by non-cash expenses such as amortization or depreciation, which are typical in biotechnology but absent here given the N/A revenue status, suggesting the primary losses stem from direct operating costs and R&D expenditures rather than fixed asset depreciation. The free cash flow stands at $-23,187,124, indicating a substantial outflow of cash required to sustain operations and fund the clinical development pipeline, which limits immediate financial flexibility but is a standard characteristic for companies in the clinical stage. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet generated commercial revenue to establish meaningful profitability ratios or cost efficiencies at scale. The company holds $117.98M in cash against a debt load of $1.45M, resulting in a debt-to-equity ratio of 1.84, which suggests a balance sheet that relies heavily on equity financing rather than traditional debt leverage despite the low absolute debt figure. The current ratio is reported at 12.23, a metric that indicates extremely strong short-term liquidity and the ability to cover short-term obligations many times over, provided the cash reserves remain intact. Return on Equity is recorded at -308.1% and return on assets at -45.1%, metrics that reveal management is currently deploying capital to generate value through future growth rather than immediate profit generation, typical for clinical-stage assets where losses are expected to widen until product approval.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to the negative net income, while the forward P/E is listed at -4.18, a metric that implies analysts are projecting continued negative earnings in the near term rather than immediate profitability. The price-to-book ratio stands at 1.76, indicating that the market values the company at a premium of 76% over its net asset book value, a valuation often seen in biotechnology firms where intangible assets like clinical trial data and intellectual property are not fully captured on the balance sheet. The price-to-sales ratio is N/A and the EV/EBITDA is -0.49, suggesting that traditional sales-based valuation multiples are not applicable, and the enterprise value relative to earnings is negative due to the cash-rich nature of the balance sheet offsetting the low market cap. The 52-week high is $11.88 and the 52-week low is $2.14, placing the current trading range within a wide band that reflects the high volatility typical of small-cap clinical-stage biotechnology stocks. The beta value is N/A, meaning the stock's price volatility relative to the broader market is not quantified in the available data, though the wide spread between the high and low prices of $11.88 and $2.14 suggests significant price instability independent of general market movements.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company is in a stage where historical growth rates cannot be calculated due to the lack of sustained commercial revenue history. Since the revenue growth and earnings growth metrics are unavailable, it is impossible to determine if earnings are growing faster or slower than revenue, as both are currently absent from the financial record. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders and retains all available capital for reinvestment into research and development activities. Given the N/A dividend yield and 0.0% payout ratio, the company reinvests its earnings, specifically the $117.98M cash reserve, directly into the advancement of its TH103 drug candidate for neovascular age-related macular degeneration rather than paying out cash to investors. The overall growth and income profile is characterized by a complete reliance on capital appreciation potential rather than income generation, with growth metrics currently undefined due to the pre-revenue status of the business.